Research

High Accuracy Modeling of SARS-CoV-2 Membrane Proteins via Machine Learning and Physics-Based Refinement

Harnessing Large-Scale Quantum-Based DFTB Calculations for a More Accurate Assessment of COVID-19 Inhibitors and Their Binding Dynamics

Computer-aided drug discovery for SARS-CoV-2

Characterization and structures of the SARS-CoV-2 polymerase and its complex with RNA or potential inhibitors

Communities of Color at Higher Risk for Health and Economic Challenges due to COVID-19

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Decoding SARS-CoV-2 transmission, evolution and ramification on COVID-19 diagnosis, vaccine, and medicine

This COVID-19 Active Cases Curve Simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to help stakeholders make decisions based on the level and trajectory of active cases in their country, region or state.

Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with COVID-19

Grifols collecting plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.

• https://www.grifols.com/en/view-news/-/news/grifols-reinforces-its-commitment-to-all-stakeholders-as-a-response-to-the-covid-19-outbreak

Kerecis Begins Omega3 Viruxide COVID-19 Trial at the National Hospital of Iceland

The FDA recommended that Revive Therapeutics proceed directly into a Phase 3 confirmatory clinical trial (“Phase 3 study”) to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection in order to ensure expeditious evaluation of the safety and efficacy of Bucillamine.

The Clinical Study of Carrimycin on Treatment Patients With COVID-19

The study team moved quickly to enroll a prospective cohort of >7,000 individuals using internet-based strategies. The cohort represents a geographically and socio-demographically diverse sample of the adult U.S. population: 23 percent of participants were 60+ years at enrollment, 24 percent are Black or Hispanic, and 52 percent are men. At least 24 percent of participants are frontline workers, either in healthcare or other essential employees such as police, first responders, people in food services or transportation. All fifty U.S. states are represented, as well as the District of Columbia, Puerto Rico, and Guam.

Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)

Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

• https://clinicaltrials.gov/ct2/show/NCT04326426

Toxicology studies initiated for anti-inflammatory drug ifenprodil

Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19

Amantadine disrupts lysosomal gene expression; potential therapy for COVID19

Network-based drug re-purposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19